|
WO2021076714A1
|
|
Methods to treat hepatitis delta viral infections
|
|
US2021121454A1
|
|
Method of treating laminopathies
|
|
WO2020081534A1
|
|
Avexitide for the treatment of hyperinsulinemic hypoglycemia
|
|
CA3109955A1
|
|
Treatment of hepatitis delta virus infection with interferon lambda
|
|
AU2018375298A1
|
|
Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis
|
|
EP3541366A1
|
|
Buffered formulations of exendin (9-39)
|
|
CN109862888A
|
|
For treating the method and pharmaceutical composition of nonalcoholic fatty liver disease
|
|
US2017296790A1
|
|
Methods and compositions for consistent intracoronary administration of a biologic
|
|
US2019060413A1
|
|
Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
|
|
EP3416675A1
|
|
Treatment of hepatitis delta virus infection with interferon lambda
|
|
US2017042862A1
|
|
Treatment of hepatitis delta virus infection
|
|
KR20180073652A
|
|
Treatment of Delta Hepatitis Virus Infection
|
|
EP3285768A1
|
|
Pharmaceutical compositions comprising lonafarnib and ritonavir
|
|
WO2016090107A2
|
|
Treatment of hepatitis delta virus infection
|
|
WO2015168648A1
|
|
Treatment of hepatitis delta virus infection
|
|
CN102666537A
|
|
Azaindazoles to treat flaviviridae virus infection
|
